Cosmetic composition for recovering skin barrier function comprising kaempferol glycoside compound

A skin protection composition with kaempferol glycoside from Camellia japonica seed cake addresses the limitations of existing cosmetics by safely improving skin wrinkles and regulating keratin production through MMP-1 and PDK1 suppression, enhancing skin regeneration and atopic dermatitis treatment.

JP2024160248AInactive Publication Date: 2024-11-13AMOREPACIFIC CORP
View PDF 7 Cites 0 Cited by

Patent Information

Application Number
JP2024117532
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-09-15
Filing Date
2024-07-23
Publication Date
2024-11-13
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Existing cosmetic materials often have insufficient efficacy or cause skin side effects, and there is a need for ingredients that can safely and effectively promote skin regeneration, improve skin wrinkles, and regulate the skin keratin production cycle.

Method used

A skin protection composition containing a kaempferol glycoside compound, particularly extracted from Camellia japonica seed cake, which suppresses Matrix Metalloprotease-1 (MMP-1) and 3-phosphoinositide-dependent kinase 1 (PDK1) to improve skin wrinkles, atopic dermatitis, and regulate keratin production.

Benefits of technology

The composition effectively improves skin wrinkles, promotes skin regeneration, and regulates the skin keratin production cycle, while being safe for human use, with the kaempferol glycoside compound showing superior effects compared to conventional compounds.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024160248000001_ABST
    Figure 2024160248000001_ABST
Patent Text Reader

Abstract

To provide a composition for skin protection containing a kaempferol compound extracted from Camellia japonica oil cake, which is discarded after extracting oil from Camellia japonica seed, as an active ingredient, which is nature-friendly, is safe for human body with few side effects, and provides superior effects such as skin regeneration.SOLUTION: A composition for skin protection comprises a kaempferol glycoside compound represented by e.g. Chemical Formula 1, an isomer thereof, a pharmaceutically acceptable salt thereof, a hydrate thereof or a solvate thereof as an active ingredient.SELECTED DRAWING: Figure 1
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] This specification discloses a skin protective composition containing a kaempferol glycoside compound that is safe for the human body and has excellent skin protective effects. [Background technology]

[0002] The skin is the primary defense membrane of the human body, protecting various internal organs from external environmental stimuli such as changes in temperature and humidity, ultraviolet rays, and pollutants, and also plays an important role in maintaining biological homeostasis, such as regulating body temperature.

[0003] However, external factors such as excessive physical and chemical stimuli, stress, and nutritional deficiencies, as well as aging, can reduce the normal functions of the skin, accelerating phenomena such as loss of elasticity, keratinization, and wrinkle formation. In order to prevent these phenomena and maintain healthier, more elastic skin, efforts have been made to use cosmetics enriched with bioactive substances to maintain the skin's inherent functions, activate skin cells, and effectively promote skin regeneration.

[0004] However, most of the existing cosmetic raw materials have various problems such as insufficient efficacy or, if their efficacy is too strong, inducing side effects on the skin. Therefore, interest is growing in ingredients that can safely and effectively promote skin regeneration and regulate the skin keratinogenesis cycle. [Prior art documents] [Non-patent literature]

[0005] [Non-Patent Document 1] BCLiau et al., Development of pressurized hot water extraction for five flavonoid glycosides from defatted Camellia oleifera seeds (byproducts), Industrial Crops and Products 95 (2017) 296-304 Summary of the Invention [Problem to be solved by the invention]

[0006] In one aspect of the present invention, an object of the present invention is to provide a composition which contains a kaempferol glycoside compound as an active ingredient, has few side effects, is safe for the human body, and has excellent skin protective effects.

[0007] In another aspect of the present invention, an object of the present invention is to provide a skin protection composition which contains, as an active ingredient, a kaempferol glycoside compound extracted from Camellia japonica seed cake, and which utilizes waste resources discarded after the extraction of Camellia seed oil.

[0008] In another aspect of the present invention, an object is to provide a composition for improving skin wrinkles or promoting skin regeneration.

[0009] In another aspect, the present invention aims to provide a composition that inhibits the expression of matrix metalloprotease-1 (MMP-1).

[0010] In another aspect of the present invention, an object is to provide a composition for improving atopic skin.

[0011] In another aspect of the present invention, an object is to provide a composition for regulating the skin keratin production cycle, or regulating skin keratin, or promoting skin keratin turnover, or normalizing the skin keratin turnover cycle.

[0012] In another aspect of the present invention, an object is to provide a composition that suppresses the activity of 3-phosphoinositide-dependent kinase 1 (PDK1) to improve atopic skin, or to improve, prevent, or treat atopic dermatitis.

[0013] In another aspect of the present invention, an object is to provide a composition that inhibits the activity of 3-phosphoinositide-dependent kinase 1 (PDK1) to regulate the keratinogenesis cycle, or regulate the keratin, or promote keratin turnover, or normalize the keratin turnover cycle. [Means for solving the problem]

[0014] The present specification provides a skin protection composition comprising, as an active ingredient, a kaempferol glycoside compound represented by any one of the following chemical formulas 1 to 4, its isomer, its pharma- ceutical acceptable salt, its hydrate or its solvate.

[0015] [ka]

[0016] [ka]

[0017] [ka]

[0018] [ka] Effect of the Invention

[0019] In one aspect, the skin protective composition disclosed in the present specification contains a kaempferol glycoside compound, in particular a kaempferol 4-glycoside compound, as an active ingredient, and is capable of improving skin wrinkles and promoting skin regeneration by suppressing the expression of matrix metalloprotease-1 (MMP-1).

[0020] In another aspect, the skin protective composition disclosed in the present specification contains a kaempferol 4-glycoside compound as an active ingredient, and is capable of improving atopic skin or improving, preventing or treating atopic dermatitis by suppressing the activity of 3-phosphoinositide-dependent kinase 1 (PDK1), and is also capable of regulating the skin keratinogenesis cycle. [Brief description of the drawings]

[0021] [Figure 1] 1 shows the results of observing the expression of the senescence marker SA-beta-gal according to one embodiment of the present invention. [Figure 2a] 1 is a graph showing the inhibitory effect of a composition according to an embodiment of the present invention on the activity of 3-phosphoinositide-dependent kinase 1 (PDK1). [Figure 2b] 1 is a graph showing the inhibitory effect of a composition according to an embodiment of the present invention on the activity of 3-phosphoinositide-dependent kinase 1 (PDK1). [Diagram 3] 1 is a graph showing the inhibitory effect of a composition according to an embodiment of the present invention on the expression of matrix metalloprotease-1 (MMP-1). [Figure 4] 1 is a graph showing the effects of a composition according to an embodiment of the present invention on H&E, Ki-67, KRT10, FLG, and INV. [Figure 5a]4 shows the effect of a composition according to an embodiment of the present invention on epidermal thickness and Ki-67. [Figure 5b] 4 shows the effect of a composition according to an embodiment of the present invention on epidermal thickness and Ki-67. [Figure 6a] 1 shows the effect of a composition according to an embodiment of the present invention on KRT10. [Figure 6b] 1 shows the effect of a composition according to an embodiment of the present invention on FLG. [Figure 6c] 1 shows the effect of a composition according to an embodiment of the present invention on INV. [Figure 7] FIG. 1 is a diagram showing information on kaempferol glycoside compounds represented by chemical formulas 1 to 4. [Figure 8a] FIG. 1 is a schematic diagram of an experiment on whether regenerative capacity is restored when PDK1l is inhibited. [Figure 8b] FIG. 1 is a schematic diagram of an experiment on whether regenerative capacity is restored when PDK1l is inhibited. [Figure 9a] These results demonstrate that inhibition of PDK1 restores the functionality of skin cells. [Figure 9b] These results demonstrate that inhibition of PDK1 restores the functionality of skin cells. [Figure 10a] These are results showing the effect of PDK1 on skin regeneration. [Figure 10b] These are results showing the effect of PDK1 on skin regeneration. [Figure 11a] 1 is a graph showing that inhibition of PDK1 suppresses the SASP in skin equivalents. [Figure 11b] 1 is a graph showing that inhibition of PDK1 suppresses the SASP in skin equivalents. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0022] In this specification, when a part "comprises" a certain component, this does not mean that other components are excluded, but that other components may also be included, unless otherwise specified.

[0023] The present invention will be described in detail below.

[0024] In an exemplary embodiment of the present invention, there is provided a composition for protecting skin, comprising, as an active ingredient, a kaempferol glycoside compound represented by any one of the following chemical formulas 1 to 4, its isomer, its pharma- ceutically acceptable salt, its hydrate, or its solvate.

[0025] [ka]

[0026] [ka]

[0027] [ka]

[0028] [ka]

[0029] As used herein, "isomer" includes in particular optical isomers (e.g., essentially pure enantiomers, essentially pure diastereomers or mixtures thereof), but also conformation isomers (i.e., isomers that differ only in the angle of one or more chemical bonds), position isomers (especially tautomers), or geometric isomers (e.g., cis-trans isomers).

[0030] As used herein, "essentially pure," when used in connection with, for example, an enantiomer or diastereomer, means that a particular compound, of which the enantiomer or diastereomer can be cited, is present in an amount of about 90% or more, preferably about 95% or more, more preferably about 97% or more, or about 98% or more, even more preferably about 99% or more, and most preferably about 99.5% or more (w / w).

[0031] As used herein, "pharmaceutical acceptable" means capable of being approved by a governmental or equivalent regulatory body for use in animals, and more particularly, in humans, by avoiding substantial toxic effects when used in normal medicinal dosages, or approved, or listed in a commonly used pharmacopoeia, or otherwise recognized as being suitable for use in commonly used pharmacopoeias.

[0032] As used herein, the term "pharmacologically acceptable salt" refers to a salt according to an aspect of the present invention that is pharma-ceutically acceptable and possesses the preferred pharmacological activity of the parent compound. The salts are formed from (1) inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or from acids such as acetic acid, propionic acid, hexanoic acid, cyclopentenepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethane-disulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, camphorsulfonic acid, 4-methylbicyclo[2,2,2]-oct-2-ene-1-carboxylic acid, glucoheptan-2-yl sulf ... or (2) salts formed when an acidic proton present in the parent compound is replaced. As used herein, the term "hydrate" refers to a compound in which water is combined, and is a broad concept that includes an encapsulated compound in which there is no chemical bonding force between the water and the mixture. As used herein, the term "solvate" refers to a higher-order compound formed between molecules or ions of a solute and molecules or ions of a solvent.

[0033] The IUPAC name of the kaempferol glycoside compound represented by Chemical Formula 1 is Kaempferol-3-O-β-D-xylopyranosyl-(1→3)-O-α-L-rhamnopyranosyl-(1→6)-O-β-D-xylopyranosyl-(1→2)-O-β-D-galactopyranoside, which may exist as a pale yellow powder at room temperature.

[0034] The information on the kaempferol glycoside compound represented by Chemical Formula 1 is as follows: Pale yellow powder;UV(HPLC-PDA)λ max 266,347 nm; [α] 22 D -57.4(c 0.10);ESI-Q-TOF-MS:m / z 859.2503[M+H] + (calcd. for C 37 H 47 O 23 + ,859.2508), 881.2329[M+Na] + (calcd. for C37 H4 6O 23 Na + , 859.2327); 1 H-(CD3OD, 500MHz) and 13 C-NMR (CD3OD, 125MHz) (see Figure 7)

[0035] The IUPAC name of the kaempferol glycoside compound represented by Chemical Formula 2 is Kaempferol-3-O-β-D-xylopyranosyl-(1→3)-O-α-L-rhamnopyranosyl-(1→6)-O-β-D-xylopyranosyl-(1→2)-O-β-D-glucopyranoside, which may exist as a pale yellow powder at room temperature.

[0036] The information on the kaempferol glycoside compound represented by Chemical Formula 2 is as follows: Pale yellow powder;UV(HPLC-PDA)λ max 266, 347 nm; [α] 22 D -63.7(c 0.10);ESI-Q-TOF-MS:m / z 859.2505[M+H] + (calcd. for C 37 H 47 O 23 + , 859.2508), 881.2325[M+Na] + (calcd. for C 37 H4 6O 23 Na + , 859.2327); 1 H-(CD3OD, 500MHz) and 13 C-NMR (CD3OD, 125MHz) (see Figure 7)

[0037] The IUPAC name of the kaempferol glycoside compound represented by the above chemical formula 3 is Kaempferol-3-O-β-D-xylopyranosyl-(1→3)-O-α-L-rhamnopyranosyl-(1→6)-O-β-D-glucopyranosyl-(1→2)-O-β-D-galactopyranoside. It may exist as a pale yellow powder at room temperature.

[0038] The information on the kaempferol glycoside compound represented by Chemical Formula 3 is as follows: Pale yellow powder;UV(HPLC-PDA)λ max 266, 347 nm; [α] 22 D -72.5(c 0.2);ESI-Q-TOF-MS:m / z 889.2616[M+H] + (calcd. for C 38 H 49 O 23 + , 8 89.2613) and 911.2432[M+Na] + (calcd. for C 38 H 48 O 24 Na + , 859.2327);1H-(CD3OD, 500MHz) and 13 C-NMR (CD3OD, 125MHz) (see Figure 7)

[0039] The IUPAC name of the kaempferol glycoside compound represented by Chemical Formula 4 is Kaempferol-3-O-β-D-xylopyranosyl-(1→3)-O-α-L-rhamnopyranosyl-(1→6)-O-β-D-glucopyranosyl-(1→2)-O-β-D-gluctopyranoside, which may exist as a pale yellow powder at room temperature.

[0040] The information on the kaempferol glycoside compound represented by the above chemical formula 4 is as follows: Pale yellow powder;UV(HPLC-PDA)λ max 266, 347 nm; [α] 22 D -45.1(c 0.10);ESI-Q-TOF-MS:m / z 889.2613[M+H] + (calcd. for C 38 H 49 O 23 + , 889.2613) and 911.2423[M+Na] + (calcd. for C 38 H 48 O 24 Na + , 859.2327); 1 H-(CD3OD, 500MHz) and 13 C-NMR (CD3OD, 125MHz) (see Figure 7)

[0041] A composition according to one aspect of the present invention contains, as an active ingredient, kaempferol tetrasaccharides extracted from Camellia japonica seed cake, which is discarded after oil is extracted from camellia seeds, and can exhibit significantly superior effects in improving skin wrinkles, regenerating skin, improving, preventing or treating atopic dermatitis, and regulating the skin keratinogenesis cycle, compared to conventional compositions containing kaempferol glycoside compounds as active ingredients.

[0042] Camellia oil cake extract is composed of terpene glycosides, flavonoid glycosides, sugars and proteins. In particular, the flavonoid glycosides in camellia oil cake are composed of kaempferol tetraglycosides (chemical formulas 1, 2, 3, 4) and triglycosides (chemical formulas 5, 6, 7, 8 below), and the present inventors have confirmed that among the kaempferol glycosides derived from camellia oil cake, four of the tetraglycosides (chemical formulas 1, 2, 3, 4) have excellent skin protection effects.

[0043] [ka]

[0044] [ka]

[0045] [ka]

[0046] [ka]

[0047] In one embodiment, the kaempferol glycoside compound may be extracted from camellia oil cake.

[0048] Specifically, the kaempferol glycoside compound may be obtained by preparing camellia oil cake obtained after squeezing oil from camellia seeds by a pressing method, and extracting the kaempferol glycoside compound from the camellia oil cake using 70% ethanol.

[0049] In one embodiment, the concentration of the active ingredient may be 0.01 to 100 μM based on the total weight of the composition, for example, 0.01 μM or more, 0.1 μM or more, 0.5 μM or more, 1 μM or more, 1.5 μM or more, 2 μM or more, or 2.5 μM or more, and may be 100 μM or less, 50 μM or less, 10 μM or less, 8 μM or less, 6 μM or less, or 4 μM or less.

[0050] If the concentration is less than 0.01 μM, the skin protective effects such as promoting skin regeneration, improving atopic dermatitis, or regulating the skin keratinogenesis cycle may be insignificant, and if the concentration exceeds 100 μM, cytotoxicity may occur.

[0051] In one embodiment, the composition may be for improving skin wrinkles.

[0052] In one embodiment, the composition may be for promoting skin regeneration.

[0053] In one embodiment, the composition may inhibit the expression of matrix metalloprotease-1 (MMP-1).

[0054] In another embodiment, the composition may be for improving skin wrinkles by suppressing expression of matrix metalloprotease-1 (MMP-1).

[0055] In yet another embodiment, the composition may be for promoting skin regeneration by inhibiting expression of matrix metalloprotease-1 (MMP-1).

[0056] In one embodiment, the composition may be for improving atopic skin.

[0057] In an embodiment, the composition may be for regulating the skin keratinogenesis cycle.

[0058] The skin keratinogenesis cycle can be said to be the turnover cycle of epidermal cells, which refers to the cycle in which keratinocytes grow from the bottom of the epidermis to degenerated keratinocytes on the surface of the skin.

[0059] The turnover cycle of skin cells can be determined by two factors: one is to maintain the growth potential of epidermal cells and measure the colony formation efficiency, and the other is to maintain barrier strength by promoting differentiation of epidermal cells and measure the degree of differentiation. According to one aspect of the present invention, the composition contains a kaempferol 4-glycoside compound as an active ingredient, and can promote colony formation and differentiation of epidermal cells to shorten the skin keratinogenesis cycle or the turnover cycle of epidermal cells.

[0060] In another embodiment, the composition may be for regulating skin keratin, or for promoting skin keratin turnover, or for normalizing the skin keratin turnover cycle.

[0061] In one embodiment, the composition may inhibit the activity of 3-phosphoinositide-dependent kinase 1 (PDK1).

[0062] When PDK1 activity is inhibited using a composition containing a kaempferol glycoside compound represented by any one of the above chemical formulas 1 to 4, cells whose growth has been inhibited due to aging can grow again and damaged cells can be restored.

[0063] In other words, inhibition of PDK1 in aged human dermal fibroblasts can eliminate aging characteristics and inhibit NF-κB and mTOR signaling, thereby restoring the cell production cycle and restoring or promoting skin regeneration ability.

[0064] In yet another embodiment, the composition may be for improving skin wrinkles by inhibiting the activity of 3-phosphoinositide-dependent kinase 1 (PDK1).

[0065] In yet another embodiment, the composition may be for promoting skin regeneration by inhibiting the activity of 3-phosphoinositide-dependent kinase 1 (PDK1).

[0066] In yet another embodiment, the composition may be for improving atopic skin or improving, preventing, or treating atopic dermatitis by inhibiting the activity of 3-phosphoinositide-dependent kinase 1 (PDK1).

[0067] In yet another embodiment, the composition may be for regulating the skin keratinogenesis cycle by inhibiting the activity of 3-phosphoinositide-dependent kinase 1 (PDK1).

[0068] In yet another embodiment, the composition may be for regulating skin keratin by inhibiting the activity of 3-phosphoinositide-dependent kinase 1 (PDK1).

[0069] In still another embodiment, the composition may be for promoting skin keratin turnover by inhibiting the activity of 3-phosphoinositide-dependent kinase 1 (PDK1).

[0070] In yet another embodiment, the composition may be for normalizing the skin keratin turnover cycle by inhibiting the activity of 3-phosphoinositide-dependent kinase 1 (PDK1).

[0071] In yet another embodiment, the composition may be for improving the skin barrier by inhibiting the activity of 3-phosphoinositide-dependent kinase 1 (PDK1). In one embodiment, the composition may be a cosmetic composition.

[0072] The cosmetic composition according to one embodiment of the present invention may be in the form of a cosmetically or dermatologically acceptable medium or base, which may be provided in any suitable form for topical application, for example in the form of a solution, a gel, a solid, a paste-free product, an emulsion obtained by dispersing an oily phase in an aqueous phase, a suspension, a microemulsion, a microcapsule, a microgranule or a vesicular dispersion of ionic (liposomes) and non-ionic type, or in the form of a cream, skin, lotion, powder, ointment, spray or concealer stick. These compositions are suitable for the application of the present invention. They may be prepared by conventional methods in the art. The compositions according to the invention may also be used in the form of an aerosol composition further comprising a compressed propellant in the form of a foam.

[0073] The cosmetic composition according to an embodiment of the present invention is not particularly limited in its formulation, and may be formulated into cosmetics such as, for example, a softening lotion, an astringent lotion, a nourishing lotion, a nourishing cream, a massage cream, an essence, an eye cream, an eye essence, a cleansing cream, a cleansing foam, a cleansing water, a pack, a powder, a body lotion, a body cream, a body oil, and a body essence.

[0074] When the dosage form according to an embodiment of the present invention is a paste, cream or gel, the carrier component may be animal fiber, vegetable fiber, wax, paraffin, starch, tragacanth, cellulose derivatives, polyethylene glycol, silicone, bentonite, silica, talc, zinc oxide, or the like.

[0075] When the dosage form according to an embodiment of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate, or polyamide powder may be used as a carrier component, and, particularly in the case of a spray, may further include a propellant such as chlorofluorohydrocarbon, propane / butane, or dimethyl ether.

[0076] When the dosage form according to an embodiment of the present invention is a solution or emulsion, the carrier component may be a solvent, solvating agent, or emulsifier, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butyl glycol oil, glycerol aliphatic esters, polyethylene glycol, propylene ... Examples of the fatty acid esters include fatty acid esters of sorbitan, glycol, or sorbitan.

[0077] When the dosage form according to one embodiment of the present invention is a suspension, the carrier component may be a liquid diluent such as water, ethanol, or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester, and polyoxyethylene sorbitan ester, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar, or tragacanth.

[0078] When the dosage form according to one embodiment of the present invention is a surfactant-containing cleanser, the carrier component may be fatty alcohol sulfate, fatty alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyl taurate, sarcosinate, fatty acid amide ether sulfate, alkylamido betaine, fatty alcohol, fatty acid glyceride, fatty acid diethanolamide, vegetable oil, lanolin derivative, or ethoxylated glycerol fatty acid ester.

[0079] The cosmetic composition according to an embodiment of the present invention may further include functional additives and ingredients contained in general cosmetic compositions in addition to the active ingredients. The functional additives may include an ingredient selected from the group consisting of water-soluble vitamins, oil-soluble vitamins, polymeric peptides, polymeric polysaccharides, sphingolipids, and seaweed extracts.

[0080] The cosmetic composition according to an embodiment of the present invention may further contain components contained in general cosmetic compositions, if necessary, together with the functional additives. Other components that may be contained include oils and fats, moisturizers, emollients, surfactants, organic and inorganic pigments, organic powders, UV absorbers, preservatives, bactericides, antioxidants, plant extracts, pH adjusters, alcohol, colorants, fragrances, blood circulation promoters, cooling agents, antiperspirants, purified water, etc. Furthermore, the composition according to one embodiment of the present invention may be a skin topical agent, and the skin topical agent It is a general term for any composition that can be applied to the skin, and can include cosmetics and pharmaceuticals in a variety of dosage forms.

[0081] In one embodiment, the composition may be a pharmaceutical composition for improving, preventing, or treating atopic dermatitis.

[0082] The pharmaceutical composition according to an embodiment of the present invention may further contain pharmaceutical adjuvants such as preservatives, stabilizers, hydrating agents or emulsifying agents, salts for adjusting osmotic pressure and / or buffering agents, and other therapeutically useful substances, and may be formulated into various oral or parenteral dosage forms according to conventional methods.

[0083] The oral dosage forms include, for example, tablets, pills, hard and soft capsules, liquids, suspensions, emulsions, syrups, powders, fine granules, granules, pellets, etc., and these dosage forms may contain, in addition to the active ingredient, surfactants, diluents (e.g., lactose, dextrose, sucrose, mannitol, sorbitol, cellulose, and glycine), lubricants (e.g., silica, talc, stearic acid and its magnesium or calcium salt, and polyethylene glycol). The tablets may further contain binders such as magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, and polyvinylpyrrolidine, and may optionally contain pharmaceutical additives such as disintegrants such as starch, agar, alginic acid or its sodium salt, absorbents, colorants, flavorings, and sweeteners. The tablets may be manufactured by conventional mixing, granulating, or coating methods. The parenteral administration form may be a transdermal administration form, such as, but not limited to, an injection, a drip infusion, an ointment, a lotion, a gel, a cream, a spray, a suspension, an emulsion, a suppository, or a patch.

[0084] The pharmaceutical composition according to an embodiment of the present invention may be administered parenterally, rectally, topically, transdermally, subcutaneously, or the like.

[0085] The determination of the dosage of the active ingredient is within the level of a person of ordinary skill in the art, and the daily dosage of the drug may vary depending on various factors such as the degree of progression of obesity, the time of onset of the disease, the age, health condition, and complications of the subject to be administered. Based on an adult, the composition may generally be administered in a dose of 0.01 mg / kg / day to 100 mg / kg / day, for example, 0.01 mg / kg / day or more, 0.1 mg / kg / day or more, 0.5 mg / kg / day or more, 1 mg / Kg / day or more, 1.3 mg / Kg / day or more, 1.5 mg / kg / day or more, or more. The dose may be 100 mg / kg / day or less, 50 mg / kg / day or less, 10 mg / kg / day or less, 7 mg / kg / day or less, 5 mg / kg / day or less, 3 mg / kg / day or less, or 2.5 mg / kg / day or less, and preferably 1 mg / kg to 5 mg / kg administered in 1 to 3 divided doses per day, and the above dosage does not limit the scope of the present invention regardless of the method.

[0086] In one embodiment, the composition may be a food composition.

[0087] The food composition according to an embodiment of the present invention may be in a liquid or solid form, such as a tablet, capsule, soft capsule, pill, granule, beverage (drink), diet bar, chocolate, caramel, or confectionery, and the dosage form is not particularly limited. In addition to the active ingredient, the food composition of the present invention may appropriately contain excipients, sugars, flavors, colorants, oils and fats, proteins, etc. as necessary. In yet another embodiment of the present invention, a kaempferol glycoside compound represented by any one of the following chemical formulas 1 to 4, an isomer thereof, a pharma- ceutically acceptable salt thereof, a hydrate thereof, or A method for protecting the skin is provided, which comprises administering to a subject in need thereof an effective amount of a composition containing the solvate as an active ingredient.

[0088] [ka]

[0089] [ka]

[0090] [ka]

[0091] [ka]

[0092] In yet another exemplary embodiment of the present invention, there is provided a use of a kaempferol glycoside compound represented by any one of the following chemical formulas 1 to 4, its isomer, its pharma- ceutically acceptable salt, its hydrate or its solvate for preparing a composition for skin protection.

[0093] [ka]

[0094] [ka]

[0095] [ka]

[0096] [ka]

[0097] In yet another exemplary embodiment of the present invention, there is provided a non-therapeutic use of a kaempferol glycoside compound represented by any one of the following chemical formulas 1 to 4, its isomer, its pharma- ceutically acceptable salt, its hydrate or its solvate for protecting skin.

[0098] [ka]

[0099] [ka]

[0100] [ka]

[0101] [ka]

[0102] In yet another exemplary embodiment of the present invention, there is provided a kaempferol glycoside compound represented by any one of the following chemical formulas 1 to 4, an isomer thereof, a pharma- ceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof for use in improving, preventing, or treating atopic dermatitis.

[0103] [ka]

[0104] [ka]

[0105] [ka]

[0106] [ka]

[0107] The present invention will be described in more detail with reference to the following examples. Note that the following examples are merely illustrative for the purpose of aiding understanding of the present invention, and are not intended to limit the scope and spirit of the present invention.

[0108] Working Example The camellia oil cake used in the experiment was obtained after the production of oil from camellia seeds in the Camellia Village on Jeju Island by pressing. An extract was produced from the camellia oil cake using 70% ethanol, and it was confirmed that the camellia oil cake extract was composed of terpene glycosides, flavonoid glycosides, sugars, and proteins. In particular, the flavonoid glycosides in camellia oil cake are composed of kaempferol tetraglycosides (chemical formulas 1-4) and triglycosides (chemical formulas 5-8), and in this specification, it was confirmed that the four types of kaempferol glycosides (chemical formulas 1-4) in the four glycosides in camellia oil cake have excellent skin anti-aging and regeneration effects.

[0109] 1) Purification of kaempferol glycoside fraction from camellia oil cake 1 kg of camellia oil cake, which had been extracted at low temperature to remove the oil, was added with 8 kg of 70% ethanol and extracted for 8 hours at 60°C using a heated extractor. The extract obtained by filtration using a filter press was concentrated under reduced pressure at 50-60°C using a rotary vacuum concentrator until the solid content was about 50%, to obtain 200 g of concentrated liquid. The concentrated liquid was diluted with purified water to a solid content of 10%. This solution was loaded into a glass tube column packed with 2 L of ion exchange resin (HP-20), and then washed with 10 L of purified water to remove impurities and sugar components. Next, 10 L of 30% ethanol was poured in, and the eluate was concentrated under reduced pressure and freeze-dried to obtain about 20 g of camellia kaempferol glycoside fraction powder.

[0110] 2) Purification of kaempferol tetraglycosides and triglycosides from camellia oil cake The components of the Camellia kaempferol glycoside fraction were separated using preparative HPLC because the difference in elution time was very small as a result of HPLC. The solvent conditions used were a mixture of water, acetonitrile, and methanol, and a concentration gradient or a fixed ratio mixture of these solvents was used. As a result, the components of the kaempferol glycoside compounds of chemical formulas 1-4 (tetraglycosides) and 5-8 (triglycosides) were separated.

[0111] Test Example statistics In all the experiments described below, statistical significance between samples was analyzed using student t-test, and a p-value of 0.05 or less was considered to be statistically significant. (*p <0.05, **p<0.01, ***p<0.001)

[0112] Test Example 1: Confirmation of the expression level of aging marker SA-beta gal *Cell lines and cultures (1) Cultivation of aged skin cells Normal human dermal fibroblasts (NHDF; Lonza, Switzerland) were cultured in DMEM medium (Dulbecco's modified Eagle's Medium, Gibco 1210-0038) containing 10% fetal bovine serum, all cultures were performed at 37°C in a 5% CO2 incubator. Cells from passages 6 to 9 were used as young cells, which were subcultured 1:5 for 37 passages to obtain aged dermal fibroblasts.

[0113] (2) Analysis of senescence marker SA-beta gal expression activity The aged skin cells of (1) above were treated with DMSO, the compounds represented by chemical formulas 1, 2, 3, 4, 5, 6, 7, and 8, and 3 μM of Kaempferol 3-O-β-rutinoside (chemical formula 9) and Kaempferol 7-O-β-D-glucopyranoside (chemical formula 10) represented by the following chemical formulas 9 and 10, respectively, for 7 days.

[0114] [ka]

[0115] [ka]

[0116] On day 8, the cells were washed with PBS and incubated with a Cellular Senescence Assay kit (Cell Biolabs, Inc., San Diego, CA). The cells were stained at 37°C for 16 hours using fixative and staining solutions provided by Biosciences, Inc. (Osaka, CA, USA). The next day, the cells were washed with PBS, covered with 20% glycerol solution, and the number of green-stained cells was counted under a microscope. The expression level of SA-beta-Gal, a senescence marker, was then evaluated. The results are shown in Table 1 and Figure 1.

[0117] [Table 1]

[0118] *Cell viability assay 1. HDF (human dermal fibroblast) cells were cultured in a 96-well plate at 1 × 10 4 The cells were then cultured under cell culture conditions for 48 hours. 2. The test substances were diluted in different concentrations in DMEM medium not containing FBS, and then applied to the cells and cultured for 48 hours. 3. The cells were washed with DPBS (Dulbecco's Phosphate-Buffered Saline), and the culture medium was replaced with 10% EZ-Cytox solution. After culturing under cell culture conditions for 1 hour, the absorbance at 450 nm was measured using an ELISA reader (Tecan Infinite M200 Pro).

[0119] Referring to Table 1, it can be seen that the compounds of Formulas 1-4 of the present invention inhibited the expression of SA-beta, an aging marker, by about 50% compared to the control group or the comparative compound (Formulas 5-8).

[0120] Also, referring to FIG. 1, it can be visually confirmed that the senescence marker SA-beta gal was significantly reduced in cells cultured with the compound of Formula 1-4 of the present invention.

[0121] Test Example 2: Analysis of PDK1 The activity of 3-phosphoinositide-dependent kinase 1 (PDK1) was measured using recombinant purified PDK1 enzyme and ADP-Glo+PDK1 Kinase Enzyme System (Promega, Madison, WI, USA). After dispensing a mixture of substrate, ATP, and buffer, test substances (1, 3, 10 μM) were dispensed into each well. Immediately after that, PDK1 was dispensed and reacted for 60 minutes. After the reaction, ADP-glo was added and incubated at room temperature for 40 minutes, and then kinase detection buffer was added and reacted for 30 minutes, after which the activity was measured using a luminescence reader (Wallac Victor2, Perkin Elmer). The results are shown in Figures 2a and 2b.

[0122] 2a and 2b, it can be seen that the PDK activity inhibitory effect of the compounds (2b) of the formulae 1 to 4 of the present invention is far superior to that of the compounds (2a) of the formulae 5 to 8 of the comparative example. Specifically, referring to FIG. 2a, it can be seen that the compounds of the formulae 5 to 8 do not inhibit PDK1 activity at all, but rather promote it, compared to the control group DMSO, whereas referring to FIG. 2b, it can be seen that the compounds of the formulae 1 to 4 of the present invention significantly inhibit PDK1 activity, compared to the control group DMSO. In addition, it can be seen that when an OH is further attached among the kaempferol 4 glycoside compounds (formulae 1 to 4), a higher effect is shown at the same concentration.

[0123] Test Example 3: MMP-1 ELISA Analysis HDF cells were cultured in a 24-well plate at 2.5 × 10 4The cells were then dispensed at a concentration of 10 ... 2 UVB (15 mJ / cm 2 After irradiation, the medium was replaced with DMEM medium containing the test substance (2 μM or 3 μM) and cultured for 48 hours. The supernatant was then collected and the amount of MMP-1 was measured using Human Total MMP-1 ELISA (R&D systems). The results are shown in Figure 3.

[0124] Referring to FIG. 3, it can be seen that the MMP-1 expression inhibition of the kaempferol tetraglycoside compound of the present invention (chemical formulas 1, 3, and 4) is superior to that of the control groups such as the kaempferol triglycoside compound (chemical formulas 5 and 7) and retinoic acid (Ra).

[0125] Test Example 4: Confirmation of improvement of skin barrier 1)3D organotypic skin epidermis Human epidermis models (Epiderm™ EPI-201; MatTek Corporation, Ashland, MA, USA) were purchased from young (21 years old, designated as 21Y) and old (58 years old, designated as 58Y) individuals, and the old human epidermis model was treated with 3 μM of kaempferol tetraglycosides, represented by the chemical formula, for 4 days. Paraffin blocks were prepared after fixation in 10% neutral buffered formalin.

[0126] 2) Confirmation of skin barrier markers After reacting with anti-KRT 10 (Biolegend, San Diego, CA), anti-FLG (Novus Biologicals, Centennial CO, USA), anti-Involucrin, and anti-Ki67 (Abcam) antibodies, the expression of each antibody was analyzed under a microscope. Specifically, epidermal tissue from a young donor (Young 21Y) and epidermal tissue from an old donor (Old 58Y) were treated with drugs, stained with the indicated antibodies, and quantified. The results are shown in Figure 4, Figures 5a-5b, and Figures 6a-6c, and Figures 5a-5b and 6a-6c are quantifications of the results of Figure 4.

[0127] In reference to this, it was confirmed that epidermal tissue from elderly people had reduced epidermal thickness (Fig. 5a), weakened barrier function (KRT10-Fig. 6a, FLG-Fig. 6b, INV-Fig. 6c), and poor expression of regenerative markers (KI67-Fig. 5b) compared to epidermal tissue from young people. Furthermore, when the epidermal tissue from elderly people was treated with the compound represented by Chemical Formula 1, the results showed that the epidermal thickness, barrier function, and expression of regenerative markers were restored to a similar extent to that of young people in all items.

[0128] Test Example 5: Recovery of regenerative ability when PDK1 is inhibited By analyzing the regulatory signal network, we predicted that PDK1 is an inhibitor target that can switch senescent fibroblasts into quiescent fibroblasts (Fig. 8a). To test this prediction, we performed experiments on normal human dermal fibroblasts (NHDFs) exposed to PDK1 inhibitors (Fig. 8b), which eliminated the hallmarks of cellular senescence. They confirmed that the compound restored cell proliferation in response to growth factors, and restored skin regeneration ability in 2D culture and in a 3D skin-equivalent model.

[0129] Overall, we found that PDK1 inhibition reduces both cell proliferation and SASP, which are key processes that maintain the senescent phenotype, and inactivates a major positive feedback loop composed of cell proliferation-related PDK1, AKT, IKBKB, and PTEN. The resulting changes in signaling restore the quiescence phenotype.

[0130] In the following experiments, normal human dermal fibroblasts (normal Human dermal fibroblasts (NHDF; Lonza, Switzerland) were cultured in DMEM medium (Dulbecco's modified Eagle's Medium, Gibco 1210-0038) containing 10% fetal bovine serum, all cultures were performed at 37°C in a 5% CO2 incubator. Cells with passage numbers 6 to 9 were considered young cells, and these were subcultured 1:5 for 37 passages to obtain aged dermal fibroblasts.

[0131] 1) Functional recovery of skin cells by PDK1 inhibition as analyzed by wound healing assay First, to determine whether PDK1 inhibition or dual inhibition of mTOR and NF-κB could achieve bona fide regenerative capabilities in addition to reducing hallmarks of aging, we examined the capacity of the reverted cells for 2D wound healing and 3D skin regeneration.

[0132] The specific experimental method is as follows.

[0133] Young NHDFs were not subjected to senescence conditions or drug treatment. Young NHDFs were analyzed when the cultures reached approximately 80% confluence at PDL 12. The remaining NHDFs were exposed to doxorubicin (100 ng / ml) and IGF-1 (100 ng / ml) for 7 days to induce senescence. For drug treatment conditions, senescent cells were further treated with DMSO, rapamycin (100 nM), rapamycin and JSH (2.5 μM), or BX795 (100 nM) for 7 days. For conditioned medium treatment (BX795+Conditioned medium), cells were grown in the presence of doxorubicin and IGF-1 for 7 days, subcultured in the additional presence of doxorubicin, IGF-1, and BX795 for 7 days, and then further cultured with conditioned medium extracted from senescent cells for 3 days.

[0134] 9a-9b, respectively: (FIG. 9a) Representative images at 0 and 96 hours after injury, with the dashed line indicating the wound site. Scale bar=200 μm. (FIG. 9b) Quantification analysis of migration area by scratch injury analysis. Mean ± SD (n=3), *** compared to DMSO control senescent cells by one-way analysis of variance. P<0.001.

[0135] PDK1 inhibition or dual inhibition of mTOR and NF-κB (but not mTOR monoinhibition) promoted the healing of scratch wounds in NHDF monolayers (FIGS. 9a-9b).

[0136] 2) Effect of PDK1 on skin regeneration As a 3D skin model (skin equivalent), we prepared young NHDFs (PDL 12) or senescent NHDFs induced to senescence by repeated plating (replicative senescence, PDL 57) and exposed them to DMSO or BX795 at the following concentrations: doxorubicin (100 mg / mL), IGF-1 (100 ng / mL), and BX-795 (100 nM).

[0137] Referring to Figures 10a to 10b, they are as follows: (10a) Skin equivalent model Sections were stained with hematoxylin and eosin (H&E) or Masson's Trichrome to detect collagen fibers. The indicated proteins were detected by immunohistochemistry. Results are from a representative experiment of three. Scale bar = 50 μm.

[0138] Specifically, the experimental method is as follows.

[0139] Paraffin samples were dewaxed in xylene and rehydrated in descending ethanol (3 min in each solution). Epitope retrieval was performed at 121°C for 10 min using a Citrate Buffer pH 6.0 Antigen Retriever (64142; Electron Microscopy Sciences, Hatfield, PA), and slides were cooled before being washed three times with PBS / 0.05% Tween 20. Sections were then incubated with water / 1% H2O2 for 30 min to block endogenous peroxidase, rinsed with water and PBS / 0.05% Tween 20 for 5 min, and incubated with PBS / 10% goat serum (Dako, Glostrup, Denmark) for 20 min before exposure to the next primary antibody overnight at 4°C. The primary antibodies were as follows: anti-KRT 10 (Biolegend, San Diego, CA), anti-FLG (Abcam), anti-MMP-1 (Abcam), and anti-Ki67 (Abcam).

[0140] Samples were washed thoroughly with water for 10 min and then with PBS / 0.05% Tween 20 for 5 min before incubation with EnVision+System-horseradish peroxidase-labeled polymeric anti-mouse antibody (K4001; Dako, Carpinteria, CA) for 30 min. Samples were then washed with water and PBS for 3–5 min before incubation with liquid DAB+ Substrate Chromogen System (K3468; Dako). The reaction was stopped by rinsing with tap water, and sections were counterstained with Mayer's hematoxylin for 3–5 min, rinsed with tap water for 1 min, and rinsed with Scott's bluing water for 2 min.

[0141] Finally, sections were dehydrated in graded ethanol, cleared in xylene, and mounted in Cytoseal 60 (ThermoScientific, Waltham, MA). Masson's trichrome staining was performed using a commercially available kit (BBC Biochemical, Seattle, WA, USA). For immunofluorescence staining, antigen retrieval was performed by boiling slides in Dako target retrieval solution (Dako) for 20 min. Nonspecific staining was blocked by incubation in PBS containing 10% donkey serum and 0.05% Triton X-100 for 30 min. Tissue sections were incubated with COL17A1 (Abcam) and Laminin 5 (Santa Cruz Biotechnology) in Dako Fluorescence Mounting Medium (Dako) overnight at 4°C, followed by Alexa Fluorescence Mounting for 2 h at room temperature. After incubation with the appropriate secondary antibody conjugated with Fluor 488 (Invitrogen-Molecular Probes), the sections were washed with PBS and incubated with 4',6-diamidine-2'-phenylindole dihydrochloride for nuclear counterstaining. DAPI (Invitrogen-Molecular Probes) was added to the coverslips, which were then mounted onto glass slides using fluorescent mounting medium (Thermo Electron).

[0142] From the top to the bottom on the left side of Figure 10b, quantification of skin thickness using ImageJ software, quantification of MMP1, quantification of pan-collagen fibers detected by Masson's Trichrome staining, quantification of Ki-67 positive cells, quantification of epidermal thickness using ImageJ software, quantification of keratin 10, quantification of filaggrin, quantification of COL17A1, quantification of Laminin5, and quantification of type I procollagen protein secreted into the culture medium quantified by ELISA. Data in Figure 10b are presented as the mean ± SD of three independent fields obtained from three independent samples. ***P<0.001 compared to DMSO control senescent cells by one-way analysis of variance.

[0143] PDK1 inhibition reversed dermal senescence associated with replicative and chemically induced senescence, evidenced by increased MMP1, decreased collagen fibers, and decreased procollagen secretion (Figures 10a-10b). In the case of epidermal homeostasis, the balance between keratinocyte proliferation and differentiation is regulated by dermal fibroblasts.

[0144] Therefore, we investigated whether reversal of senescent dermal fibroblasts by inhibition of PDK1 affects proliferation and differentiation of keratinocytes. BX-795 is a potent PDK1 inhibitor that blocks PDK1 / Akt signaling in tumor cells and inhibits anchorage-dependent growth of various tumor cell lines in culture or with induced apoptosis. Our results showed that Ki-67 proliferation marker was significantly elevated in the epidermis of skin equivalents treated with BX795 (Fig. 10a-10b), a well-known PDK1 inhibitor, indicating that senescence-induced NDHF increased the proliferation capacity of keratinocytes, preserving the epidermal thickness in skin equivalents (Fig. 10a-10b).

[0145] Furthermore, comparison of staining intensity for keratinocyte differentiation markers (keratin 10 and filaggrin) and basement membrane markers of the dermal-epidermal junction (COL17A1 and laminin 5) showed that PDK1 inhibition restored the decreased abundance of such keratinocyte differentiation markers and components of the dermal-epidermal junction found in aged NHDF skin equivalents (Figure 10a).

[0146] Similar to the observations for 2-D aged NHDFs (Figures 9a-9b), conditioned medium extracted from skin equivalents prepared from the two types of aged NHDFs treated with BX795 was prepared to contain less GRO, GROα, IL-6, IL-8, MCP-1-3, and RANTES than conditioned medium from vehicle-treated skin equivalents (Figures 11a-11b).

[0147] Specifically, the experimental method is as follows.

[0148] PDK1 inhibition suppresses SASP in skin equivalents. 3D skin models (skin equivalents) were prepared with young NHDFs (PDL 12) or senescent NHDFs induced to senescence by doxorubicin and IGF-1 or repeated plating (replicative senescence, PDL 57) and exposed to DMSO or BX795 at the following concentrations: doxorubicin (100 mg / mL), IGF-1 (100 ng / mL), and BX-795 (100 nM).

[0149] Conditioned medium (CM) from skin equivalents of chemically-induced or replicative senescent NHDFs treated with or without BX795 was measured by cytokine antibody array and normalized as an internal positive control for each membrane. (Figure 11a) Secreted proteins measured by cytokine array of skin equivalents from chemically-induced NHDFs treated with or without BX795. (Figure 11b) Secreted proteins measured by cytokine array of skin equivalents from chemically-induced NHDFs treated with or without BX795. Secreted proteins measured by cytokine array of skin equivalents from non-replicate senescent NHDFs. Mean ± SD (n=3) compared to DMSO control senescent cells by one-way analysis of variance, ***P<0.001.

[0150] Overall, these findings indicate that PDK1 inhibition switches senescent dermal fibroblasts into quiescent fibroblasts, enhancing epidermal regeneration and preserving skin thickness, limiting aging-associated skin deterioration.

[0151] Examples Example 1: A skin protection composition comprising as an active ingredient a kaempferol glycoside compound represented by any one of the following chemical formulas 1 to 4, its isomer, its pharma- ceutically acceptable salt, its hydrate or its solvate.

[0152] [ka]

[0153] [ka]

[0154] [ka]

[0155] [ka]

[0156] Example 2: In Example 1, A skin protecting composition, wherein the kaempferol glycoside compound is extracted from camellia oil cake.

[0157] Example 3: In Example 1 or 2, A composition for protecting skin, wherein the concentration of the active ingredient is 0.01 to 100 μM based on the total weight of the composition.

[0158] Specific Example 4: In any one of Specific Examples 1 to 3, The skin protection comprises: Improve skin wrinkles; Promoting skin regeneration; Suppression of matrix metalloprotease-1 (MMP-1) expression; Improving, preventing or treating atopic dermatitis; Regulating the skin's keratinocyte production cycle; or A composition for protecting the skin, which inhibits the activity of 3-phosphoinositide-dependent kinase 1 (PDK1).

[0159] Specific Example 5: In any one of Specific Examples 1 to 4, The composition is a cosmetic composition, which is a skin protecting composition.

[0160] Example 6: In any one of Examples 1 to 4, The composition is a pharmaceutical composition for improving, preventing or treating atopic dermatitis, and is a composition for protecting the skin.

[0161] Example 7: In any one of Examples 1 to 6, A composition for protecting skin, wherein the dosage of the active ingredient is 0.01 to 100 mg / kg / day.

[0162] Example 8: In any one of Examples 1 to 4, The composition for skin protection is a food composition.

Claims

1. A skin protecting composition comprising, as an active ingredient, a kaempferol glycoside compound represented by any one of the following chemical formulas 1 to 4, an isomer thereof, a pharma- ceutical acceptable salt thereof, a hydrate thereof or a solvate thereof: [Formula 1] [Case 2] [C3] [C4]

2. 2. The skin protecting composition according to claim 1, wherein the kaempferol glycoside compound is extracted from camellia oil cake.

3. 3. The composition for protecting skin according to claim 1, wherein the concentration of the active ingredient is from 0.01 to 100 μM based on the total weight of the composition.

4. The skin protection comprises: Improve skin wrinkles; Promoting skin regeneration; Suppressing the expression of matrix metalloprotease-1 (MMP-1); Improving, preventing or treating atopic skin; Regulating the skin keratinogenesis cycle; or The composition for protecting the skin according to any one of claims 1 to 3, wherein the effect is to inhibit the activity of 3-phosphoinositide-dependent kinase 1 (PDK1).

5. The composition for protecting skin according to any one of claims 1 to 4, wherein the composition is a cosmetic composition.

6. The composition for protecting skin according to any one of claims 1 to 4, which is a pharmaceutical composition for improving, preventing or treating atopic dermatitis.

7. The composition for protecting skin according to claim 6, wherein the dosage of the active ingredient is 0.01 to 100 mg / kg / day.

8. The composition for protecting skin according to any one of claims 1 to 4, wherein the composition is a food composition.

Citation Information

Patent Citations

  • Emulsion type cosmetic

    JP1986260005A

  • Skin ameliorating agent and oral composition for beauty and health

    JP2008137998A

  • External preparation for skin

    JP2008201773A

  • Anti-inflammatory agent and skin external medicine

    JP2009155317A

  • Oral composition

    JP2012067082A